Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

Autor: Kathryn Pritchard-Jones, Anne-Sophie DEFACHELLES, Sucheta Vaidya, Gustaf Ljungman, Norbert Graf, Marc Ansari, Gordan Vujanic, Ricardo López Almaraz, Pedro Zubizarreta, Jan Godziński, Pamela Kearns, Anna Llort, Beatriz De Camargo, Leo Kager, Harm Van Tinteren, Ingrid Øra

Publikováno v: Pritchard-Jones, K, Bergeron, C, de Camargo, B, van den Heuvel-Eibrink, M M, Acha, T, Godzinski, J, Oldenburger, F, Boccon-Gibod, L, Leuschner, I, Vujanic, G, Sandstedt, B, de Kraker, J, van Tinteren, H, Graf, N & SIOP Renal Tumours Study Group 2015, ' Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001) : an open-label, non-inferiority, randomised controlled trial ', Lancet, vol. 386, no. 9999, pp. 1156-1164 . https://doi.org/10.1016/S0140-6736(14)62395-3
Lancet, 386(9999), 1156-1164. Elsevier Limited
The Lancet, Vol. 386, No 9999 (2015) pp. 1156-64

BACKGROUND: Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is importa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05386b33380bcd2146bacb31bab8c77a
https://doi.org/10.1016/s0140-6736(14)62395-3

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.